These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 68766)
41. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Johansson BE Vaccine; 1999 Apr; 17(15-16):2073-80. PubMed ID: 10217609 [TBL] [Abstract][Full Text] [Related]
42. [Radioimmunological analysis of the neuraminidase of influenza virus subtype N2]. Gitel'man AK; Zakomyrdin IuA; Kharitonenkov IG Vopr Virusol; 1983; 28(5):556-61. PubMed ID: 6659471 [TBL] [Abstract][Full Text] [Related]
43. [Antigenic properties of influenza virus type A inactivated by ultraviolet irradiation]. Bokhnevich GM; Fridman EA; Peradze TV Vopr Virusol; 1978; (1):74-9. PubMed ID: 77085 [TBL] [Abstract][Full Text] [Related]
45. [Antigenic characteristics of different variants of influenza virus A(H3/N2) and their circulation in the USSR and People's Republic of Bulgaria in 1968-1980]. Zakstel'skaia LIa; Nikolova Z; Iakhno MA; Shenderovich SF; Oskerko TA Vopr Virusol; 1982; 27(6):671-6. PubMed ID: 6186088 [TBL] [Abstract][Full Text] [Related]
46. [On the antigenicity of influenza virus aluminum oxide adjuvant vaccine "Alorbat" in man (author's transl)]. Desselberger U; Pressler K; Erdmann G Zentralbl Bakteriol Orig A; 1975 Jul; 232(2-3):160-77. PubMed ID: 1179878 [TBL] [Abstract][Full Text] [Related]
47. Genetic composition of a high-yielding influenza A virus recombinant: a vaccine strain against "Swine" influenza. Palese P; Ritchey MB; Schulman JL; Kilbourne ED Science; 1976 Oct; 194(4262):334-5. PubMed ID: 968486 [TBL] [Abstract][Full Text] [Related]
48. Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase. Yoshikawa T; Suzuki Y; Nomoto A; Sata T; Kurata T; Tamura Si Vaccine; 2002 Nov; 21(1-2):60-6. PubMed ID: 12443663 [TBL] [Abstract][Full Text] [Related]
49. Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase. Epstein SL; Misplon JA; Lawson CM; Subbarao EK; Connors M; Murphy BR J Immunol; 1993 Jun; 150(12):5484-93. PubMed ID: 8390536 [TBL] [Abstract][Full Text] [Related]
50. Directed selection of amino acid changes in the influenza hemagglutinin and neuraminidase affecting protein antigenicity. DeDiego ML; Chiem K; Topham DJ Vaccine; 2018 Oct; 36(43):6383-6392. PubMed ID: 30224200 [TBL] [Abstract][Full Text] [Related]
51. Neuraminidase-inhibition assay for the identification of influenza A virus neuraminidase virus subtype or neuraminidase antibody specificity. Pedersen JC Methods Mol Biol; 2014; 1161():27-36. PubMed ID: 24899417 [TBL] [Abstract][Full Text] [Related]
52. Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98). Gulati U; Hwang CC; Venkatramani L; Gulati S; Stray SJ; Lee JT; Laver WG; Bochkarev A; Zlotnick A; Air GM J Virol; 2002 Dec; 76(23):12274-80. PubMed ID: 12414967 [TBL] [Abstract][Full Text] [Related]
53. Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics. Lu B; Zhou H; Ye D; Kemble G; Jin H J Virol; 2005 Jun; 79(11):6763-71. PubMed ID: 15890915 [TBL] [Abstract][Full Text] [Related]
55. Characteristics of antigenic and biological properties of influenza A viruses isolated different epidemics of the same cycle. Luzjanina TY; Golubev DB; Ivanova NA; Grinbaum EB; Zykov MP Ann Microbiol (Paris); 1975 Dec; 126(4):461-70. PubMed ID: 59567 [TBL] [Abstract][Full Text] [Related]
56. Preparation of influenza B virus recombinant strains. Podchernyaeva RYa ; Shchipanova MV; Elkin VS; Melnichenko EI Acta Virol; 1987 Nov; 31(6):475-80. PubMed ID: 2894141 [TBL] [Abstract][Full Text] [Related]
57. Protection against lethal influenza with neuraminidase. Webster RG; Reay PA; Laver WG Virology; 1988 May; 164(1):230-7. PubMed ID: 2452514 [TBL] [Abstract][Full Text] [Related]
58. Roles of antibodies to influenza A virus hemagglutinin, neuraminidase, and M2e in conferring cross protection. Kim YJ; Ko EJ; Kim MC; Lee YN; Kim KH; Jung YJ; Kang SM Biochem Biophys Res Commun; 2017 Nov; 493(1):393-398. PubMed ID: 28887040 [TBL] [Abstract][Full Text] [Related]
59. A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. Babai I; Barenholz Y; Zakay-Rones Z; Greenbaum E; Samira S; Hayon I; Rochman M; Kedar E Vaccine; 2001 Nov; 20(3-4):505-15. PubMed ID: 11672916 [TBL] [Abstract][Full Text] [Related]
60. Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans. Kilbourne ED J Infect Dis; 1976 Oct; 134(4):384-94. PubMed ID: 789791 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]